Achieve Life Sciences (STU:SP4P) EPS (Diluted): €-0.96 (TTM As of Mar. 2026)


STU:SP4P Achieve Life Sciences Inc STU:SP4P
32 GF Score
Price €5.35
! 4 Warning Signs
View Full Analysis

What is Achieve Life Sciences EPS (Diluted)?

Achieve Life Sciences STU:SP4P -3.60% 32 EPS (Diluted) is €-0.96 as of Mar. 2026. GuruFocus rates STU:SP4P with a GF Score™ of 32/100. The stock has 4 warning signs investors should review.

Achieve Life Sciences's Earnings per Share (Diluted) for the three months ended in Mar. 2026 was €-0.16. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was €-0.96.

Achieve Life Sciences's EPS (Basic) for the three months ended in Mar. 2026 was €-0.16. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was €-0.96.

Achieve Life Sciences's EPS without NRI for the three months ended in Mar. 2026 was €-0.17. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 was €-0.96.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.


Achieve Life Sciences  (STU:SP4P) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Achieve Life Sciences EPS (Diluted) Related Terms


Achieve Life Sciences EPS (Diluted) Historical Data

* Premium members only.

The historical data trend for Achieve Life Sciences's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Achieve Life Sciences EPS (Diluted) Chart

Achieve Life Sciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS (Diluted)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.61 -3.78 -1.38 -1.18 -1.07

Achieve Life Sciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EPS (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.34 -0.32 -0.24 -0.24 -0.16

STU:SP4P vs STTK, CRMD, EIKN: EPS (Diluted) Comparison

For the Biotechnology subindustry, Achieve Life Sciences's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Achieve Life Sciences PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Achieve Life Sciences's PE Ratio distribution charts can be found below:

* The bar in red indicates where Achieve Life Sciences's PE Ratio falls into.


STU:SP4P
32GF Score
Achieve Life Sciences Inc STU:SP4P
EPS (Diluted) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Achieve Life Sciences EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Achieve Life Sciences's Diluted EPS for the fiscal year that ended in Dec. 2025 is calculated as

Diluted EPS (A: Dec. 2025 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-46.669-0)/43.595
=-1.07

Achieve Life Sciences's Diluted EPS for the quarter that ended in Mar. 2026 is calculated as

Diluted EPS (Q: Mar. 2026 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-8.795-0)/53.382
=-0.16

EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.96

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Diluted) →
What does a EPS (Diluted) of €-0.96 mean?
Achieve Life Sciences (STU:SP4P) has a EPS (Diluted) of €-0.96 as of Mar. 2026. Earnings per share (diluted) equals net income divided by the diluted average shares outstanding. View historical data on Achieve Life Sciences and its competitors.
Is Achieve Life Sciences' EPS (Diluted) too high?
Achieve Life Sciences' current EPS (Diluted) is €-0.96. Overall, Achieve Life Sciences has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Achieve Life Sciences' EPS (Diluted) compare to STTK and CRMD?
Achieve Life Sciences' EPS (Diluted) of €-0.96 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Diluted) for a Biotechnology company?
A good EPS (Diluted) depends on the Biotechnology industry context. However, EPS (Diluted) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Diluted) mean?
A high EPS (Diluted) can signal that a stock is expensive relative to its fundamentals. Earnings per share (diluted) equals net income divided by the diluted average shares outstanding. View historical data on Achieve Life Sciences and its competitors. Achieve Life Sciences's current EPS (Diluted) is €-0.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Achieve Life Sciences stock overvalued right now?
Achieve Life Sciences (STU:SP4P) has a current EPS (Diluted) of €-0.96. The current EPS (Diluted) is €-0.96. Achieve Life Sciences' overall GF Score™ is 32/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Diluted) calculated?
EPS (Diluted) is calculated from a company's financial statements. For Achieve Life Sciences (STU:SP4P), the current EPS (Diluted) is €-0.96 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Achieve Life Sciences Business Description

Other Exchanges ACHV:USASP4P:Germany
Address 22722 29th Drive SE, Suite 100, Bothell, WA, USA, 98021
Achieve Life Sciences Inc is a late-stage clinical specialty pharmaceutical company with the sole mission to address the nicotine dependence epidemic through the development and commercialization of cytisinicline. Cytisinicline, is a naturally occurring alkaloid. Additionally, The company has completed a Phase 2 study with cytisinicline in vaping cessation and conducted a successful end-of-Phase 2 meeting with the FDA for a future vaping indication. It operates in one operating segment, development and commercialization of cytisinicline for nicotine dependence, with operations located in Canada, the United States and the U.K.
32GF Score

Get the complete analysis for STU:SP4P

EPS (Diluted) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.35
Price